---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-024345"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T01:04:12.290354+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Ironwood reports FY2023 GAAP net loss of $1.0B; LINZESS sales $1.1B (+7%)

## Summary
- FY2023 total revenue $442.7M; LINZESS collaboration revenue $430M; Q4 revenue $117.6M.
- FY2023 GAAP net loss attributable to Ironwood $1.002B ($6.45 diluted loss/share), vs FY2022 net income $175M.
- LINZESS U.S. net sales $1.1B (+7% YoY), prescription demand +10% YoY; pediatric IBS-C approval in June 2023.
- Expects topline STARS Phase 3 study of apraglutide in SBS-IF in March 2024; CNP-104 Phase 2 data in Q3 2024.
- FY2023 adjusted EBITDA loss $884.8M (includes impairment), vs positive $251.8M in FY2022.

## SEC filing metadata
- accession: 0001104659-24-024345
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465924024345/0001104659-24-024345-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465924024345/tm246124d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-024345
- JSON: https://secwatch.observer/filing/0001104659-24-024345.json
- Plain text: https://secwatch.observer/filing/0001104659-24-024345.txt

## Key facts
- Earnings Releases
  IRONWOOD PHARMACEUTICALS INC reported the quarter ended December 31, 2023 results: revenue $ 117,553, net income (1,087), EPS (0.01).
  - Period: the quarter ended December 31, 2023
  - Revenue: $ 117,553
  - Net income: (1,087)
  - EPS: (0.01)
  - Result: reported results
  source text: Fourth Quarter and Full Year 2023 Financial Highlights 1 (in thousands, except for per share amounts) Q4 2023 Q4 2022 FY 2023 FY 2022 Total revenues $ 117,553 $ 107,199 $ 442,735 $ 410,596 Total operating expenses 2 79,964 38,836 1,388,165 160,259 GAAP net income (loss) 2 (1,745 ) 48,867 (1,031,559 ) 175,065 GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. 2 (1,087 ) - (1,002,239 ) - GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. per share – basic (0.01 ) 0.32 (6.45 ) 1.13 GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. per share – diluted (0.01 ) 0.27 (6.45 ) 0.96
  evidence_url: https://www.sec.gov/Archives/edgar/data/1446847/000110465924024345/0001104659-24-024345-index.htm
- Earnings Releases
  IRONWOOD PHARMACEUTICALS INC reported the year ended December 31, 2023 results: revenue $ 442,735, net income (1,002,239), EPS (6.45).
  - Period: the year ended December 31, 2023
  - Revenue: $ 442,735
  - Net income: (1,002,239)
  - EPS: (6.45)
  - Result: reported results
  source text: Fourth Quarter and Full Year 2023 Financial Highlights 1 (in thousands, except for per share amounts) Q4 2023 Q4 2022 FY 2023 FY 2022 Total revenues $ 117,553 $ 107,199 $ 442,735 $ 410,596 Total operating expenses 2 79,964 38,836 1,388,165 160,259 GAAP net income (loss) 2 (1,745 ) 48,867 (1,031,559 ) 175,065 GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. 2 (1,087 ) - (1,002,239 ) - GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. per share – basic (0.01 ) 0.32 (6.45 ) 1.13 GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. per share – diluted (0.01 ) 0.27 (6.45 ) 0.96
  evidence_url: https://www.sec.gov/Archives/edgar/data/1446847/000110465924024345/0001104659-24-024345-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.